- Home
- SES vs BNTC Comparison
SES vs BNTC Comparison
Compare SES & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SES
- BNTC
- Stock Information
- Founded
- SES 2012
- BNTC 1995
- Country
- SES United States
- BNTC United States
- Employees
- SES N/A
- BNTC N/A
- Industry
- SES Auto Parts:O.E.M.
- BNTC Biotechnology: Pharmaceutical Preparations
- Sector
- SES Consumer Discretionary
- BNTC Health Care
- Exchange
- SES Nasdaq
- BNTC Nasdaq
- Market Cap
- SES 384.0M
- BNTC 365.1M
- IPO Year
- SES N/A
- BNTC N/A
- Fundamental
- Price
- SES $2.75
- BNTC $13.90
- Analyst Decision
- SES Buy
- BNTC Strong Buy
- Analyst Count
- SES 1
- BNTC 5
- Target Price
- SES $2.00
- BNTC $24.80
- AVG Volume (30 Days)
- SES 15.8M
- BNTC 40.3K
- Earning Date
- SES 10-30-2025
- BNTC 11-13-2025
- Dividend Yield
- SES N/A
- BNTC N/A
- EPS Growth
- SES N/A
- BNTC N/A
- EPS
- SES N/A
- BNTC N/A
- Revenue
- SES $11,360,000.00
- BNTC N/A
- Revenue This Year
- SES $883.92
- BNTC N/A
- Revenue Next Year
- SES $159.98
- BNTC N/A
- P/E Ratio
- SES N/A
- BNTC N/A
- Revenue Growth
- SES N/A
- BNTC N/A
- 52 Week Low
- SES $0.20
- BNTC $9.09
- 52 Week High
- SES $3.05
- BNTC $17.15
- Technical
- Relative Strength Index (RSI)
- SES 83.76
- BNTC 54.74
- Support Level
- SES $1.57
- BNTC $13.49
- Resistance Level
- SES $2.01
- BNTC $14.01
- Average True Range (ATR)
- SES 0.25
- BNTC 0.54
- MACD
- SES 0.09
- BNTC -0.04
- Stochastic Oscillator
- SES 82.51
- BNTC 64.70
About SES SES AI Corporation
SES AI Corp is a developer and manufacturer of high-performance, AI-enhanced Lithium-Metal (Li-Metal) and Lithium-ion (Li-ion) rechargeable battery technologies for electric vehicles (EVs), Urban Air Mobility (UAM), drones, robotics, Battery Energy Storage Systems (BESS) and other applications. It includes Software and Hardware products that are EV, UAM, Drone, Molecular Universe, and Avatar.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.